Lipoproteína(a)
Grupo Argentino Estudio Lipoproteína (a)
.png)
Novedades Mayo 2026
Front Endocrinol (Lausanne). 2026 Apr 21:17:1795181. doi: 10.3389/fendo.2026.1795181. eCollection 2026.
Autores:
Song Wen 1 , Yanju He 1 , Xiucai Li 1 , Zhimin Xu 1 , Dan Liu 2 , Jiyu Li 3 , Ligang Zhou 1
Conclusión: Elevated Lp(a) levels are significantly associated with CVD and demonstrate strong discriminative utility, particularly in patients with DM. These findings suggest that more stringent Lp(a) thresholds may be warranted in the clinical management of diabetic patients to better identify individuals at high risk for cardiovascular outcomes.
Heart Lung Circ. 2026 May;35(5):606-619. doi: 10.1016/j.hlc.2025.11.017. Epub 2026 Apr 21.
Autores:
David Eccleston 1 , Enayet K Chowdhury 2 , Anna Williamson 3 , Meherin Rahman 4 , Catherine Sciascia 4 , Ravi Santani 4 , Renae Deans 2
Conclusión: The study revealed that Lp(a) testing is underutilised among patients with ASCVD in Australia despite recent guidelines recommending it. This emphasises the need to expand Lp(a) testing to improve health outcomes for high-risk patients.
Heart Lung Circ. 2026 May;35(5):620-626. doi: 10.1016/j.hlc.2026.01.007. Epub 2026 Apr 20.
Autores:
Caroline A E Bachmeier 1 , Greg J Ward 2 , Ashley Arnott 2 , Behzad Kiani 3 , Andrew J Kassianos 4 , Michael M Page 5 , Karam M Kostner 6
Conclusión: Lp(a) testing has grown substantially in Queensland and Australia over the past decade, likely reflecting increased recognition of its causal role in cardiovascular disease, evolving guideline recommendations, test accessibility, and the emergence of novel therapies. However, overall testing remains limited. Broader implementation of guideline-based testing and greater clinician awareness will be critical to ensure timely identification of individuals who may benefit from available and emerging therapeutic strategies.
Life Sci. 2026 Jul 1:396:124371. doi: 10.1016/j.lfs.2026.124371. Epub 2026 Apr 3.
Autores:
Parmis Mansouri 1 , Reza Golchin Vafa 2
Rev Port Cardiol. 2026 May;45(5):217-226. doi: 10.1016/j.repc.2025.11.012. Epub 2026 Mar 26.
Autores:
Catarina Carrapa 1 , Marta Leite 2 , Francisca Saraiva 3 , Sílvia O Diaz 3 , António S Barros 3 , Inês Neves 2 , Marta Almeida 2 , Diogo Santos Ferreira 4 , Gualter Santos Silva 2 , Francisco Sampaio 4 , Eduardo Vilela 5 , Ricardo Fontes-Carvalho 4
Conclusión: Lp(a) levels showed a heterogeneous distribution and were not associated with traditional cardiovascular risk factors or other lipid parameters. This reinforces Lp(a) as an independent risk factor, supporting active screening in patients with ACS, particularly in women not affected by traditional cardiovascular risk factors.
Acta Cardiol. 2026 May;81(3):414-423. doi: 10.1080/00015385.2026.2643431. Epub 2026 Mar 17.
Autores:
Thitiphan Srikulmontri 1 2 , Suchanart Pantarote 3 , Narathorn Kulthamrongsri 4 , Phuuwadith Wattanachayakul 1 2 , Wasawat Vutthikraivit 5 , Aman Amanullah 2 6
Conclusión: Elevated Lp(a) levels were associated with a higher risk of repeat revascularization and TVR, with a non-significant trend towards increased TLR. Further studies are warranted to confirm these findings and explore the potential benefit of Lp(a)-lowering strategies.
J Atheroscler Thromb. 2026 May 1;33(5):566-577. doi: 10.5551/jat.65904. Epub 2025 Dec 11.
Autores:
Yudai Niwa 1 , Hiroyuki Naruse 2 , Hideki Kawai 1 , Eirin Sakaguchi 2 , Yuya Ishihara 2 , Hidekazu Hattori 2 , Komei Uehara 2 , Masaki Ito 2 , Shingo Yamada 3 , Akira Yamada 1 , Takashi Muramatsu 1 , Fumihiko Kitagawa 4 , Hiroshi Takahashi 1 , Junnichi Ishii 1 , Masayoshi Sarai 1 , Masanobu Yanase 1 , Yukio Ozaki 4 , Kuniaki Saito 5 , Hideo Izawa 1
Conclusión: The combinatorial value of assessing Lp(a) levels and Suita score may provide useful insight regarding Japanese patients undergoing CCTA for the prediction of HRP.
Cardiovasc Revasc Med. 2026 May:86:67-77. doi: 10.1016/j.carrev.2025.07.003. Epub 2025 Jul 8.
Autores:
Mick P L Renkens 1 , Tsung-Ying Tsai 2 , Pruthvi C Revaiah 3 , Shigetaka Kageyama 4 , Johan H C Reiber 5 , Robbert J de Winter 6 , Maik Grundeken 6 , Nick S Nurmohamed 7 , Erik Stroes 8 , Scot Garg 9 , Clemens von Birgelen 10 , Sjoerd Hofma 11 , Mohammad Alkhalil 12 , Liesbeth Rosseel 13 , Faisal Sharif 14 , Pieter C Smits 15 , Andreas Baumbach 16 , Yoshinobu Onuma 17 , Joanna J Wykrzykowska 18 , Patrick W Serruys 19
Conclusión: Elevated plasma levels of Lp(a) were associated with increased epicardial flow limitation and a more diffuse endoluminal disease pattern.
J Int Med Res. 2026 Apr;54(4):3000605261436667. doi: 10.1177/03000605261436667. Epub 2026 Apr 30.
Autores:
Zhe Liu 1 , Hui Li 2 , Wen Chang 3 , Baoyu Geng 1 , Lei Wu 1 , Zhen Chen 1
Front Endocrinol (Lausanne). 2026 Apr 13:17:1780579. doi: 10.3389/fendo.2026.1780579. eCollection 2026.
Autores:
Feifei Wang # 1 2 , Jiangnan Wu # 3 , Hongling Li # 4 , Shijie Gao 2 , Zhuohan Zheng 2 , Zhiheng Wang 1 2 , Jing Gao 1
Conclusión: Low Lp(a) levels within the first 20 weeks of gestation were associated with the subsequent development of GDM, independent of maternal age and pre-pregnancy BMI.
Pharmacol Res. 2026 May:227:108178. doi: 10.1016/j.phrs.2026.108178. Epub 2026 Apr 3.
Autores:
An-Xin Wu 1 , Xing-Jin Wang 2 , Chen Zhao 3 , Jia-Qiang Hu 4 , Jin-Wei Li 5 , Ying Xu 6 , Yi Li 7 , Song Liu 8
Pol Arch Intern Med. 2026 Apr 29;136(4):17253. doi: 10.20452/pamw.17253. Epub 2026 Mar 17.
Autores:
Grzegorz Procyk, Paweł Tyrna, Izabela Młynarczuk-Biały, Jan Budzianowski, Anna Olasińska-Wiśniewska, Janusz Kochman, Aleksandra Gąsecka
Conclusión: The patients with elevated Lp(a) level had a comparable risk of 12‑month MACCE after TAVI to those with low Lp(a) level but might have worse long‑term survival. Long‑term findings should be considered exploratory and require further confirmation.
Am Heart J. 2026 Jul:297:107423. doi: 10.1016/j.ahj.2026.107423. Epub 2026 Mar 7.
Autores:
Emiliano Bianchini 1 , Sara Essa Alsubai 2 , Foziyah Alqahtani 2 , Sara Sgreva 3 , Paolo Alberto Del Sole 1 , Aduba Chukwunwike 4 , Despina Abrasheva 5 , Vasanth Cherin 4 , Hesham Elzomor 4 , Ruth Sharif 6 , Michael G Madden 7 , Faisal Sharif 8
Conclusión: Distinct biomarker signatures associate with distinct CAD prevalence and severity that conventional lipid markers fail to distinguish. Lp(a) appears relevant for early plaque detection in coronary artery calcium = 0 patients. A comprehensive biomarker evaluation may help identifying high-risk subgroups overlooked by a conventional assessment.
Am J Cardiol. 2026 May 15:267:97-103. doi: 10.1016/j.amjcard.2026.02.038. Epub 2026 Feb 26.
Autores:
Eleni Adamopoulou 1 , Kyriakos Dimitriadis 2 , Athanasios Sakalidis 3 , Konstantinos Kyriakoulis 3 , Alexandros Koulouriotis 3 , Nikolaos Pyrpyris 3 , Konstantinos Aznaouridis 3 , Philippos Orfanos 4 , Pagona Lagiou 4 , Konstantinos Tsioufis 3
Adv Med Sci. 2026 Mar;71(1):68-74. doi: 10.1016/j.advms.2026.02.006. Epub 2026 Feb 26.
Autores:
Joanna Popiolek-Kalisz 1 , Pierre Sabouret 2
Conclusión: In high cardiovascular risk patients, Lp(a) appears unrelated to body composition, supporting its role as a non-modifiable, genetically driven risk factor. Conversely, despite pharmacotherapy, HDL-C and triglycerides demonstrated significant associations with body fat distribution. These findings suggest clinical role of body composition assessment in cardiovascular risk management, particularly in addressing residual risk beyond LDL-C.
Curr Opin Lipidol. 2026 Jun 1;37(3):107-112. doi: 10.1097/MOL.0000000000001029. Epub 2026 Feb 13.
Autores:
Martine Paquette 1 , Simon-Pierre Guay 2 , Alexis Baass 1 3
Curr Opin Lipidol. 2026 Jun 1;37(3):93-99. doi: 10.1097/MOL.0000000000001032. Epub 2026 Feb 10.
Autores:
Ali K Jaafar 1 , Steeve Bourane 2 , Gilles C Lambert 2 , Kevin Chemello 3
Eur Heart J Cardiovasc Imaging. 2026 Apr 30;27(5):1012-1021. doi: 10.1093/ehjci/jeag024.
Autores:
Rebecca Fisher 1 , Chen Gurevitz 2 3 , Edward A Fisher 1 , Jisuk Park 4 , Melissa Aquino 4 , Sascha N Goonewardena 5 , Robert S Rosenson 2
Conclusión: In asymptomatic primary prevention patients, Lp(a) was independently associated with high-risk coronary plaque features, specifically LDNCP, beyond traditional risk enhancers. These findings highlight the unique role of Lp(a) in identifying coronary plaque vulnerability and suggest complementary roles for Lp(a) and CAC in refining cardiovascular risk stratification.
Front Immunol. 2026 Apr 24:17:1808231. doi: 10.3389/fimmu.2026.1808231. eCollection 2026.
Autores:
Sicong Li # 1 2 , Yiyuan Cui # 1 , Yijing Yan 1 , Hao Li 3 , Yue Jin 3 , Yufan Chen 1 , Jingjie Yu 3 , Li Feng 1
Conclusión: High LPA expression in the serum was a risk factor for metastatic driver gene-negative lung adenocarcinoma patients receiving first-line chemoimmunotherapy. Our models had favorable value in predicting PFS and G3/4 AEs, which might assist in identifying patients less likely to benefit from initial chemoimmunotherapy.
Brain Behav. 2026 May;16(5):e71475. doi: 10.1002/brb3.71475.
Autores:
Xinyi Chen 1 2 , Yueyu Zhang 1 2 , Yi Tang 1 2 , Jie Hu 1 2 , Xun He 3 , Juncang Wu 1 2
Conclusión: Lp(a) is a stable and independent predictor of poor 3-month outcomes in AIS patients, exhibiting a clear threshold effect at 31.2 mg/dL. The combined Lp(a)-NIHSS model enhances prognostic accuracy, supporting Lp(a) as a valuable biomarker for early risk stratification.
Lipids Health Dis. 2026 Apr 2;25(1):128. doi: 10.1186/s12944-026-02938-x.
Autores:
Alpo Vuorio 1 , Anniina Ojanen 2 , Tarja Palosaari 2 , Tuija Jääskeläinen 2 , Pekka Jousilahti 2 , Maija Ruuth 3 , Terhi Vihervaara 2 , Mari Savolainen 3 , Lara Lehtoranta 2 , Petri T Kovanen 4 , Annamari Lundqvist 5
Conclusión: Approximately one in ten Finnish adults had elevated Lp(a), a lower prevalence than in many other European populations but still affecting a substantial share of the population. Elevated Lp(a) was associated with higher prevalence of dyslipidemia prior to Lp(a) correction, but not with other CVD risk factors, and these individuals also showed slightly greater awareness and treatment of dyslipidemia. These findings emphasize the need for comprehensive management of modifiable CVD risk factors to reduce the overall burden of CVDs.
Cardiovasc Drugs Ther. 2026 Jun;40(3):1187-1202. doi: 10.1007/s10557-025-07810-1. Epub 2025 Nov 20.
Autores:
Rami A Al-Horani 1 2 , Alexandra C Selico-Dunn 3 , Emily Lauren Schenk Smith 3
Conclusión: As novel therapies advance and clinical guidelines evolve, Lp(a) is emerging as a central determinant in personalized cardiovascular care. The increasing emphasis on Lp(a) testing underscores its importance in risk stratification and future therapeutic decisionmaking.
Medicine (Baltimore). 2026 May 22;105(21):e48919. doi: 10.1097/MD.0000000000048919.
Autores:
Wenzhi Du 1 2 , Dazheng Li 2 , Na Li 3 , Wenxiu Zhang 4 , Jianning Wang 2 , Tianyi Wang 1 , Yong Zeng 1
Clin Lab. 2026 May 1;72(5). doi: 10.7754/Clin.Lab.2025.250664.
Autores:
S Drobnik, A Koloi, H Scharnagl, T Hollstein, U Kassner, A Dressel, W Drobnik, M Nauck, W März
Conclusión: The influence of Lp(a) on the determination of LDL-C may lead to clinically significant overestimations of the actual LDL-C. Therefore, we recommend using Lp(a)-corrected LDL-C when 1) the Lp(a) concentration is high, 2) the LDL-C concentration is low, and 3) the LDL-C-lowering treatment is less effective than expected.